PAUL HONGO: Open Payments
NPI 1598004954 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,734 in 85 payments from 18 companies in 2025. Trend: 2023 $1,673 · 2024 $1,317 · 2025 $1,734
Food & beverage: $1,734
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 20 | $537 |
| ABBVIE INC. | 26 | $396 |
| ViiV Healthcare Company | 10 | $215 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Lilly USA, LLC | 4 | $76 |
| Merck Sharp & Dohme LLC | 2 | $60 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $44 |
Products named: VRAYLAR, QULIPTA, REXULTI, APRETUDE, CABENUVA, Biktarvy, PIFELTRO, KISUNLA.
Industry payments across CO — which companies pay providers there.
